Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BMS-660368

- PMLiVE

ViiV files two-drug HIV maintenance regimen

SWORD studies show treatment could maintain viral suppression

- PMLiVE

Gilead plans fightback against HIV arch-rival ViiV

Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq

Bristol-Myers Squibb (BMS) building

BMS claims a win in mid-stage NASH trial

Its new liver disease therapy reduces fatty deposits and improves blood lipid profiles

Bristol Myers Squibb logo

Apexigen and BMS team up for lung cancer immunotherapy trial

Opdivo and APX005M used together may improve immune reaction

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

- PMLiVE

BMS closes in on colorectal cancer indication for Opdivo

Gains US priority review to treat patients with dMMR or MSI-H colorectal cancer

- PMLiVE

Opdivo gets FDA green light to treat bladder cancer

BMS adds new US indication to its checkpoint inhibitor

- PMLiVE

Efficacy trials get underway for HIV vaccine in South Africa

Study hopes to provide partial immunity against the virus

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

ViiV takes two-drug cocktail for first-line HIV into phase III

New approach hopes to reduce drug exposure and improve adherence

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Research Partnership

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links